{
    "root": "13425085-7611-4d10-b76d-5b64b8438692",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Cimzia",
    "value": "20240919",
    "ingredients": [
        {
            "name": "CERTOLIZUMAB PEGOL",
            "code": "UMD07X179E"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "cimzia tumor necrosis factor ( tnf ) blocker indicated : reducing signs symptoms crohn 's disease maintaining response adult patients moderately severely active disease inadequate response conventional therapy ( 1.1 ) treatment adults moderately severely active rheumatoid arthritis ( 1.2 ) treatment active polyarticular juvenile idiopathic arthritis ( pjia ) patients 2 years age older ( 1.3 ) treatment adult patients active psoriatic arthritis . ( 1.4 ) treatment adults active ankylosing spondylitis ( 1.5 ) treatment adults active non-radiographic axial spondyloarthritis objective signs inflammation ( 1.6 ) treatment adults moderate-to-severe plaque psoriasis candidates systemic therapy phototherapy ( 1.7 )",
    "contraindications": "cimzia administered subcutaneous injection . injection sites rotated injections given areas skin tender , bruised , red hard . 400 mg dose needed ( given two subcutaneous injections 200 mg ) , injections occur separate sites thigh abdomen . solution carefully inspected visually particulate matter discoloration prior . solution clear opalescent , colorless yellow liquid , essentially free particulates used cloudy foreign particulate matter present . cimzia contain preservatives ; therefore , unused portions remaining syringe vial discarded .",
    "warningsAndPrecautions": null,
    "adverseReactions": "cimzia contraindicated patients history hypersensitivity reaction certolizumab pegol excipients . included angioedema , anaphylaxis , serum sickness , urticaria [ ( 5.4 ) ] .",
    "indications_original": "CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 )",
    "contraindications_original": "CIMZIA is administered by subcutaneous injection. Injection sites should be rotated and injections should not be given into areas where the skin is tender, bruised, red or hard. When a 400 mg dose is needed (given as two subcutaneous injections of 200 mg), injections should occur at separate sites in the thigh or abdomen.\n                  The solution should be carefully inspected visually for particulate matter and discoloration prior to administration. The solution should be a clear to opalescent, colorless to yellow liquid, essentially free from particulates and should not be used if cloudy or if foreign particulate matter is present.  CIMZIA does not contain preservatives; therefore, unused portions of drug remaining in the syringe or vial should be discarded.",
    "adverseReactions_original": "CIMZIA is contraindicated in patients with a history of hypersensitivity reaction to certolizumab pegol or to any of the excipients. Reactions have included angioedema, anaphylaxis, serum sickness, and urticaria [see Warnings and Precautions (5.4)]."
}